Entering text into the input field will update the search result below

Rafarma Pharmaceuticals, Inc. (RAFA) Targets Fair Share Of Russia's Rapidly Growing Pharmaceutical Market

Jul. 08, 2013 5:56 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Rafarma Pharmaceuticals constructed and now operates a 270,000-square foot multi-purpose pharmaceutical facility in Russia in direct response to the Russian Government's plan to significantly advance the domestic pharmaceutical industry in the Russian Federation.

In a recent video interview with the QualityStocks Production team, Rafarma CEO Sergey Brunsnitsyn details the operations and qualification of the production plant, how it meets world standards in the field of pharmaceuticals and industrial construction, and the company's strategy to secure 5 percent of market share in the Russian pharmaceuticals market by 2017.

"The strategies of the company, the professional team, the modern production facilities and our projects allow us to look forward with confidence and ensure the presence of high-quality generics and innovative medical products for our Russian and foreign consumers," Brunsnitsyn says in the interview.

To view the entire video production visit videos.qualitystocks.net

For more information visit rafarma.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.